Adverse effects of retinoids.

M David, E Hodak, N J Lowe
{"title":"Adverse effects of retinoids.","authors":"M David,&nbsp;E Hodak,&nbsp;N J Lowe","doi":"10.1007/BF03259940","DOIUrl":null,"url":null,"abstract":"<p><p>Oral retinoids, synthetic derivatives of vitamin A, have been used in the treatment of various dermatoses over the last decade. The most useful drugs have been isotretinoin (13-cis-retinoic acid) for nodulocystic acne and etretinate for psoriasis vulgaris. Retinoids are also effective in the treatment of papulosquamous dermatoses other than psoriasis (i.e. inherited disorders of keratinisation), cutaneous T-cell lymphoma and in chemotherapy and chemoprevention of cancer. However, systemic administration of these compounds is frequently associated with mucocutaneous side effects, liver toxicity and abnormalities of serum lipid profiles, which might be related to an increased risk of coronary heart disease. Of particular concern is the teratogenic effect of all retinoids, which limits their use in women of child-bearing potential. Chronic toxicities from long term therapy with retinoids may result in skeletal abnormalities, usually mimicking diffuse idiopathic hyperostosis syndrome. Furthermore, the chronic use of retinoids in children may inhibit their growth due to premature epiphyseal closure. In contrast to other side effects of retinoids which are dose dependent and reversible upon withdrawal of the drug, it seems unlikely that bone abnormalities will resolve after discontinuation of the medication. In view of the wide spectrum of toxicities, treatment with retinoids requires appropriate selection of patients, careful consideration of the benefit to risk ratio for each individual, periodic monitoring of clinical response and laboratory tests. Clinicians should use special management techniques in order to prevent or minimize slide effects. Extensive investigations are currently being conducted in an attempt to develop new retinoids which will improve the therapeutic efficacy and reduce unwanted reactions.</p>","PeriodicalId":77748,"journal":{"name":"Medical toxicology and adverse drug experience","volume":"3 4","pages":"273-88"},"PeriodicalIF":0.0000,"publicationDate":"1988-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/BF03259940","citationCount":"119","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Medical toxicology and adverse drug experience","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/BF03259940","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 119

Abstract

Oral retinoids, synthetic derivatives of vitamin A, have been used in the treatment of various dermatoses over the last decade. The most useful drugs have been isotretinoin (13-cis-retinoic acid) for nodulocystic acne and etretinate for psoriasis vulgaris. Retinoids are also effective in the treatment of papulosquamous dermatoses other than psoriasis (i.e. inherited disorders of keratinisation), cutaneous T-cell lymphoma and in chemotherapy and chemoprevention of cancer. However, systemic administration of these compounds is frequently associated with mucocutaneous side effects, liver toxicity and abnormalities of serum lipid profiles, which might be related to an increased risk of coronary heart disease. Of particular concern is the teratogenic effect of all retinoids, which limits their use in women of child-bearing potential. Chronic toxicities from long term therapy with retinoids may result in skeletal abnormalities, usually mimicking diffuse idiopathic hyperostosis syndrome. Furthermore, the chronic use of retinoids in children may inhibit their growth due to premature epiphyseal closure. In contrast to other side effects of retinoids which are dose dependent and reversible upon withdrawal of the drug, it seems unlikely that bone abnormalities will resolve after discontinuation of the medication. In view of the wide spectrum of toxicities, treatment with retinoids requires appropriate selection of patients, careful consideration of the benefit to risk ratio for each individual, periodic monitoring of clinical response and laboratory tests. Clinicians should use special management techniques in order to prevent or minimize slide effects. Extensive investigations are currently being conducted in an attempt to develop new retinoids which will improve the therapeutic efficacy and reduce unwanted reactions.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
类维生素a的副作用。
口服类维生素A是维生素A的合成衍生物,在过去十年中已被用于治疗各种皮肤病。最有用的药物是治疗结节性痤疮的异维甲酸(13-顺式维甲酸)和治疗寻常型牛皮癣的异维甲酸。类维生素a在治疗除牛皮癣以外的丘疹鳞状皮肤病(即遗传性角化疾病)、皮肤t细胞淋巴瘤以及化疗和化学预防癌症方面也有效。然而,这些化合物的全身给药通常与皮肤粘膜副作用、肝毒性和血脂异常有关,这可能与冠心病风险增加有关。特别值得关注的是所有类维生素a的致畸作用,这限制了它们在有生育能力的妇女中的使用。长期使用类维生素a治疗的慢性毒性可导致骨骼异常,通常类似于弥漫性特发性骨质增生综合征。此外,儿童长期使用类维生素a可能会由于骨骺过早闭合而抑制其生长。类维生素a的其他副作用是剂量依赖性的,停药后是可逆的,与此相反,骨异常似乎不太可能在停药后消失。鉴于毒性范围广泛,用类维生素a治疗需要适当选择患者,仔细考虑每个人的利益与风险比,定期监测临床反应和实验室检查。临床医生应使用特殊的管理技术,以防止或尽量减少滑动的影响。目前正在进行广泛的研究,试图开发新的类维生素a,以提高治疗效果并减少不良反应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
Poisoning due to class 1B antiarrhythmic drugs. Lignocaine, mexiletine and tocainide. Fulminant hyperkalaemia and multiple complications following ibuprofen overdose. Problems and pitfalls in the use of hyperbaric oxygen for the treatment of poisoned patients. A prolonged QTc interval. Is it an important effect of antiarrhythmic drugs? Clinical features and management of poisoning due to potassium chloride.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1